Product Pipeline
Find out about the anti-cancer drugs we have in development
Press Releases
-
NCCN Oncology Research Program Announces Projects Selected for Funding to Study Futibatinib in Tumors with Aberrant FGFR Expression, in Collaboration with Taiho Oncology
-
Stephen Yoder, MD, MBA Named Vice President, Business Development, at
Taiho Oncology, Inc.
-
Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML